Informed ConsentNCT07756515
Chatbot Implementation In The Clinical Informed Consent Process
A study testing CoCo Chatbot in people with Informed Consent, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The purpose of this study is to determine the feasibility of implementing the chatbot "CoCo" in the IC process for research studies. We hypothesize that implementing a chatbot into the IC process will facilitate accurate information delivery and enhance participant comprehension and process satisfaction compared to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Informed Consent
- What is being tested?
- CoCo Chatbot
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Sep 2026to 17 Dec 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to understand and willingness to provide informed consent.
- Age ≥18 years.
- Patients whose preferred language is English.
- Patients who are being considered for enrollment in selected clinical research studies.
- Phase I will be initiated using the Clearinghouse protocol PA11-0852, a non-interventional biomarker study.
Who cannot join
- N/A
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UT MD Anderson
Houston, Texas, 77030
Funda Meric-Bernstam, MD, 713-794-1226, fmeric@mdanderson.org
Funda Meric-Bernstam, MD
About this study
The purpose of this study is to determine the feasibility of implementing the chatbot "CoCo" in the IC process for research studies. We hypothesize that implementing a chatbot into the IC process will facilitate accurate information delivery and enhance participant comprehension and process satisfaction compared to traditional remote consent methods.
Read the detailed description
Primary Objectives:
- To determine the feasibility of implementing a chatbot-facilitated remote informed consent (IC) process.
Secondary Objectives
- To identify determinants of patient acceptance and usage of the chatbot.
- To determine the accuracy and completeness of information delivered via the chatbot.
- To determine the quality of the chatbot-facilitated remote IC process.
- To determine the feasibility of using the chatbot for patient eligibility verification.
- Conditions
- Informed Consent
- Being tested
- CoCo Chatbot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CoCo ChatbotOther
A patient-facing chatbot designed to obtain informed consent
| Study group | Role | What they receive |
|---|---|---|
| Phase I Feasibility Cohort: Remote IC Process for Non-Therapeutic Studies | Experimental | All participants will be provided with an abbreviated informed consent form describing this study and providing sufficient information for patients to make an informed decision regarding participation. Receives: Other: CoCo Chatbot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2026
- Study start11 Sep 2026
- Primary completion17 Dec 2028 (estimated)
- Study completion17 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Informed ConsentStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Funda Meric-Bernstam, MD, Principal investigator, UT MD Anderson
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07756515
- Sponsor's protocol ID
- 2026-0841
- Other IDs
- NCI-2026-05849
- Status last verified
- Oct 2026
- First submitted
- 7 Aug 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chatbot Implementation In The Clinical Informed Consent Process
- ClinicalTrials.gov ID
- NCT07756515
- Acronym / sponsor ID
- 2026-0841
- Conditions
- Informed Consent
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 11 Sep 2026 (actual)
- Primary completion
- 17 Dec 2028 (estimated)
- Study completion
- 17 Dec 2031 (estimated)
- First posted
- 10 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the feasibility of implementing the chatbot "CoCo" in the IC process for research studies. We hypothesize that implementing a chatbot into the IC process will facilitate accurate information delivery and enhance participant comprehension and process satisfaction compared to traditional remote consent methods.
Detailed description
Primary Objectives:
- To determine the feasibility of implementing a chatbot-facilitated remote informed consent (IC) process.
Secondary Objectives
- To identify determinants of patient acceptance and usage of the chatbot.
- To determine the accuracy and completeness of information delivered via the chatbot.
- To determine the quality of the chatbot-facilitated remote IC process.
- To determine the feasibility of using the chatbot for patient eligibility verification.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Phase I Feasibility Cohort: Remote IC Process for Non-Therapeutic Studies | Experimental | Other: CoCo ChatbotAll participants will be provided with an abbreviated informed consent form describing this study and providing sufficient information for patients to make an informed decision regarding participation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Ability to understand and willingness to provide informed consent.
- Age ≥18 years.
- Patients whose preferred language is English.
- Patients who are being considered for enrollment in selected clinical research studies.
- Phase I will be initiated using the Clearinghouse protocol PA11-0852, a non-interventional biomarker study.
Key exclusion criteria (1 listed)
- N/A
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CoCo ChatbotA patient-facing chatbot designed to obtain informed consent | Other | Phase I Feasibility Cohort: Remote IC Process for Non-Therapeutic Studies |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- http://www.mdanderson.orgLink provided by the sponsor.
Related trials for Informed Consent
Recruiting
Improving Surgical Communication for Patients in Wisconsin
Surgeons, Surgical Procedure, Unspecified
Recruiting
Effect of Video -Based vs Standard ınformation on Maternal Anxiety and Procedure Decision in Pregnant Woman Offered Amniocentesis or Cvs
Maternal Anxiety, Prenatal Diagnosis
Not yet recruitingObservational study
Risk Sharing vs Risk Dumping: Parental Attitudes About Risks
Pediatric Surgery, Informed Consent
Recruiting
Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)
Stroke, Stroke (CVA) or Transient Ischemic Attack
Not yet recruitingObservational study
Shared Decision-Making During Anesthesia Consent for Elective Cesarean Delivery
Shared Decision Making, Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Funda Meric-Bernstam, MD principal investigator
UT MD Anderson
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CoCo Chatbot in people with Informed Consent, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Funda Meric-Bernstam, MD ((713) 794-1226, fmeric@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.